Zogenix Reports Second Quarter 2012 Financial Results
08. August 2012 16:01 ET
|
Zogenix
Reiterates 2012 Financial Guidance
Conference Call and Webcast Today, August 8th, at 4:30 p.m. ET
SUMAVEL® DosePro® (sumatriptan injection) Second Quarter 2012 Highlights...
Zogenix Repays Outstanding Loan With Oxford Finance LLC and Silicon Valley Bank
01. August 2012 08:30 ET
|
Zogenix
SAN DIEGO, Aug. 1, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Announces Conference Call and Webcast to Present Second Quarter 2012 Financial Results
31. Juli 2012 07:30 ET
|
Zogenix
SAN DIEGO, July 31, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix and Battelle Launch "Less is More" DosePro(R) Marketing Campaign
30. Juli 2012 07:30 ET
|
Zogenix
SAN DIEGO and COLUMBUS, Ohio, July 30, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous...
Zogenix Prices Public Offering of Common Stock and Warrants to Purchase Common Stock
24. Juli 2012 09:04 ET
|
Zogenix
SAN DIEGO, July 24, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
23. Juli 2012 16:12 ET
|
Zogenix
SAN DIEGO, July 23, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Announces U.S. Food and Drug Administration (FDA) Acceptance for Review of Zohydro ER(TM) New Drug Application (NDA) for Treatment of Chronic Pain
16. Juli 2012 07:30 ET
|
Zogenix
SAN DIEGO, July 16, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Begins Relday(TM) Clinical Trial for Schizophrenia
12. Juli 2012 07:30 ET
|
Zogenix
Patient Screening and Enrollment Underway With Results Anticipated Before Year-End
First-in-Class Needle-Free Once-Monthly Formulation Using DosePro® Delivery System
SAN DIEGO, July 12,...
Zogenix and Mallinckrodt, a Covidien Company, Enter Exclusive Co-Promotion Agreement for SUMAVEL(R) DosePro(R)
07. Juni 2012 07:30 ET
|
Zogenix
SAN DIEGO, June 7, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,...
Zogenix Submits IND for Second DosePro(R) Candidate Relday(TM)
30. Mai 2012 07:30 ET
|
Zogenix
SAN DIEGO, May 30, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,...